---
title: "UV-related Tumor Mutational Burden Predicts Melanoma Mortality in Stage II/III InterMEL Cohort"
id: "medrxiv-11-uv-induced-mutations-are-associated-with-melanoma-specific-mortality-in-stage"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-11-uv-induced-mutations-are-associated-with-melanoma-specific-mortality-in-stage"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.18.26368442v1?rss=1"
published_at: "2026-11-20T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# UV-related Tumor Mutational Burden Predicts Melanoma Mortality in Stage II/III InterMEL Cohort
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-11-uv-induced-mutations-are-associated-with-melanoma-specific-mortality-in-stage
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.18.26368442v1?rss=1)
- **Published At:** 2026-11-20T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The InterMEL consortium analyzed 656 stage II/III primary melanomas to examine associations between mutational burden subtypes and melanoma-specific mortality. - Investigators separated **UV-induced TMB** from non-UV TMB rather than treating total TMB as a single metric; this distinction was central to the analysis. - Higher **UV TMB** was associated with improved melanoma-specific survival in this stage II/III cohort, according to the authors. - The study team observed no association between **non-UV TMB** and mortality, suggesting different biological effects by mutation origin. - Data indicated that previously reported ties between total TMB and outcome may be driven mainly by UV-related mutations rather than all mutation classes equally. - The findings replicate patterns previously reported in advanced melanoma and extend them into clinically encountered stage II/III tumors. - The report did not resolve mechanistic explanations; authors noted potential roles for neo-antigenicity, immune recognition, or other biological properties but did not provide definitive evidence. - The InterMEL investigators deposited study data on dbGaP (accession phs003099.v2.p1); IRB approval and participant consent procedures were reported by the authors. - The paper is a medRxiv preprint posted November 20, 2026; authors declared no competing interests and listed multiple NIH funding sources. - Remaining questions include the immunologic basis of the association, potential clinical utility of UV TMB measurement in early-stage melanoma, and validation in independent cohorts.
## Clinical Analysis & Structured Key Points
UV-induced Mutations are Associated with Melanoma-Specific Mortality in Stage II/III Melanomas from the InterMEL study | medRxiv Skip to main content UV-induced Mutations are Associated with Melanoma-Specific Mortality in Stage II/III Melanomas from the InterMEL study View ORCID Profile Adam Z. Reynolds , Li Luo , Ronglai Shen , Arshi Arora , Irene Orlow , Klaus J Busam , Cecilia Lezcano , Tim K Lee , Eva Hernando , Ivan Gorlov , Christopher Amos , Marc S Ernstoff , Venkat Seshan , Anne E Cust , James S Wilmott , Graham Mann , Ismael A Vergara , Eduardo Nagore , Pauline Funchain , Jennifer Ko , Sharon N Edmiston , Kathleen Conway , Paul B Googe , David Ollila , Jeffrey E Lee , Judy R Rees , Cheryl L Thompson , Meg Gerstenblith , Marcus Bosenberg , Bonnie E Gould Rothberg , Iman Osman , Yvonne Saenger , Matthew Schwartz , Tawny Boyce , Sheri L Holmen , Shaofeng Yang , Elise Brunsgaard , Paul Bogner , Pei Fen Kuan , Colin B Begg , Nancy E Thomas , Marianne Berwick , for the InterMEL Consortium doi: https://doi.org/10.64898/2026.11.18.26368442 Adam Z. Reynolds 1 University of New Mexico; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Adam Z. Reynolds For correspondence: adreynolds{at}salud.unm.edu Li Luo 1 University of New Mexico; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ronglai Shen 2 Memorial Sloan Kettering Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Arshi Arora 2 Memorial Sloan Kettering Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Irene Orlow 2 Memorial Sloan Kettering Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Klaus J Busam 2 Memorial Sloan Kettering Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Cecilia Lezcano 2 Memorial Sloan Kettering Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Tim K Lee 3 British Columbia Cancer Research Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Eva Hernando 4 NYU Grossman School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ivan Gorlov 5 Baylor Medical Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Christopher Amos 1 University of New Mexico; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Marc S Ernstoff 6 National Cancer Institute; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Venkat Seshan 2 Memorial Sloan Kettering Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Anne E Cust 7 Melanoma Institute Australia; Find this author on Google Scholar Find this author on PubMed Search for this author on this site James S Wilmott 7 Melanoma Institute Australia; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Graham Mann 8 Cleveland Clinic Foundation; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ismael A Vergara 7 Melanoma Institute Australia; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Eduardo Nagore 9 Instituto Valenciano de Oncologia; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Pauline Funchain 10 Stanford Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jennifer Ko 8 Cleveland Clinic Foundation; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sharon N Edmiston 11 Penn State University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kathleen Conway 12 University of North Carolina; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Paul B Googe 12 University of North Carolina; Find this author on Google Scholar Find this author on PubMed Search for this author on this site David Ollila 12 University of North Carolina; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jeffrey E Lee 13 MD Anderson Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Judy R Rees 14 Dartmouth Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Cheryl L Thompson 15 Case Western Reserve University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Meg Gerstenblith 15 Case Western Reserve University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Marcus Bosenberg 16 Yale University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Bonnie E Gould Rothberg 17 University of Miami Miller School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Iman Osman 4 NYU Grossman School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yvonne Saenger 18 Columbia University Medical School; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Matthew Schwartz 1 University of New Mexico; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Tawny Boyce 1 University of New Mexico; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sheri L Holmen 19 University of Utah; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Shaofeng Yang 14 Dartmouth Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Elise Brunsgaard 19 University of Utah; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Paul Bogner 20 Roswell Park Comprehensive Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Pei Fen Kuan 21 Stony Brook University Find this author on Google Scholar Find this author on PubMed Search for this author on this site Colin B Begg 2 Memorial Sloan Kettering Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Nancy E Thomas 12 University of North Carolina; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Marianne Berwick 1 University of New Mexico; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Data/Code Preview PDF Abstract The prognostic significance of tumor mutational burden (TMB) in melanoma remains controversial. One potential reason for the mixed results is that total TMB treats all mutations as biologically equivalent, despite evidence that different types of mutations contribute differently to a tumor's neo-antigenic profile. In particular, UV-induced and non-UV mutations may have distinct effects on tumor behavior and outcomes, but this hypothesis has been studied primarily in advanced-stage disease. We analyzed 656 stage II/III tumors from the InterMEL study to evaluate whether UV TMB and non-UV TMB are associated with melanoma-specific mortality and clinicopathologic factors. Higher UV TMB was associated with improved outcomes, while non-UV TMB was not associated with mortality. These findings suggest that an association between total TMB and outcome may be driven disproportionately by mutations associated with UV mutagenesis. Although this has previously been reported in advanced melanomas, our work demonstrates that the prognostic relevance of UV TMB extends to stage II/III tumors typically found in the clinical context. Whether this relationship reflects differences in tumor neo-antigenicity, immune recognition, or other biological properties remains to be determined. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Institutional Review Board of The University of New Mexico Health Sciences Center gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data used in this analysis are available on dbGaP, at accession number phs003099.v2.p1 https://dbgap.ncbi.nlm.nih.gov/study/phs003099.v2.p1/#study Funder Information Declared National Institutes of Health , 1P01CA206980-01A1 , R01CA251339 , R01CA233524 , R33CA160138 , 5P30CA118100-15 , P30CA016086 , P30CA008748 , P30CA016672 , P50CA225450 , P30ES010126 , R01CA112243 , 1T32GM135128 National Institutes of Health , 1T32GM135128 , 1K08CA151645-0 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted November 20, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following UV-induced Mutations are Associated with Melanoma-Specific Mortality in Stage II/III Melanomas from the InterMEL study Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share UV-induced Mutations are Associated with Melanoma-Specific Mortality in Stage II/III Melanomas from the InterMEL study Adam Z. Reynolds , Li Luo , Ronglai Shen , Arshi Arora , Irene Orlow , Klaus J Busam , Cecilia Lezcano , Tim K Lee , Eva Hernando , Ivan Gorlov , Christopher Amos , Marc S Ernstoff , Venkat Seshan , Anne E Cust , James S Wilmott , Graham Mann , Ismael A Vergara , Eduardo Nagore , Pauline Funchain , Jennifer Ko , Sharon N Edmiston , Kathleen Conway , Paul B Googe , David Ollila , Jeffrey E Lee , Judy R Rees , Cheryl L Thompson , Meg Gerstenblith , Marcus Bosenberg , Bonnie E Gould Rothberg , Iman Osman , Yvonne Saenger , Matthew Schwartz , Tawny Boyce , Sheri L Holmen , Shaofeng Yang , Elise Brunsgaard , Paul Bogner , Pei Fen Kuan , Colin B Begg , Nancy E Thomas , Marianne Berwick , for the InterMEL Consortium medRxiv 2026.11.18.26368442; doi: https://doi.org/10.64898/2026.11.18.26368442 Share This Article: Copy Citation Tools UV-induced Mutations are Associated with Melanoma-Specific Mortality in Stage II/III Melanomas from the InterMEL study Adam Z. Reynolds , Li Luo , Ronglai Shen , Arshi Arora , Irene Orlow , Klaus J Busam , Cecilia Lezcano , Tim K Lee , Eva Hernando , Ivan Gorlov , Christopher Amos , Marc S Ernstoff , Venkat Seshan , Anne E Cust , James S Wilmott , Graham Mann , Ismael A Vergara , Eduardo Nagore , Pauline Funchain , Jennifer Ko , Sharon N Edmiston , Kathleen Conway , Paul B Googe , David Ollila , Jeffrey E Lee , Judy R Rees , Cheryl L Thompson , Meg Gerstenblith , Marcus Bosenberg , Bonnie E Gould Rothberg , Iman Osman , Yvonne Saenger , Matthew Schwartz , Tawny Boyce , Sheri L Holmen , Shaofeng Yang , Elise Brunsgaard , Paul Bogner , Pei Fen Kuan , Colin B Begg , Nancy E Thomas , Marianne Berwick , for the InterMEL Consortium medRxiv 2026.11.18.26368442; doi: https://doi.org/10.64898/2026.11.18.26368442 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Dermatology Subject Areas All Articles Addiction Medicine (642) Allergy and Immunology (928) Anesthesia (355) Cardiovascular Medicine (5060) Dentistry and Oral Medicine (496) Dermatology (433) Emergency Medicine (681) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1704) Epidemiology (16353) Forensic Medicine (37) Gastroenterology (1250) Genetic and Genomic Medicine (7334) Geriatric Medicine (761) Health Economics (1101) Health Informatics (5352) Health Policy (1480) Health Systems and Quality Improvement (1847) Hematology (604) HIV/AIDS (1389) Infectious Diseases (except HIV/AIDS) (16537) Intensive Care and Critical Care Medicine (1210) Medical Education (702) Medical Ethics (157) Nephrology (757) Neurology (7669) Nursing (380) Nutrition (1144) Obstetrics and Gynecology (1308) Occupational and Environmental Health (1046) Oncology (3769) Ophthalmology (1105) Orthopedics (414) Otolaryngology (474) Pain Medicine (508) Palliative Medicine (144) Pathology (727) Pediatrics (1877) Pharmacology and Therapeutics (759) Primary Care Research (793) Psychiatry and Clinical Psychology (6187) Public and Global Health (10051) Radiology and Imaging (2562) Rehabilitation Medicine and Physical Therapy (1540) Respiratory Medicine (1280) Rheumatology (666) Sexual and Reproductive Health (814) Sports Medicine (601) Surgery (809) Toxicology (109) Transplantation (321) Urology (309)
## Related Clinical Research

- [Foundation-Model Whole-Slide AI plus PRAME IHC for Melanoma Diagnosis](https://medichelpline.com/clinical-feed/medrxiv-19-integrating-histopathology-foundation-models-and-prame-immunohistochemistry-in.md)
- [ESMO recap: Reactions to Merck and Moderna’s mRNA cancer vaccine data](https://medichelpline.com/clinical-feed/stat-news-1-assessing-merck-and-moderna-s-mrna-cancer-vaccine.md)
- [Deep learning on routine histopathology adds prognostic value beyond AJCC stage in early-stage mel](https://medichelpline.com/clinical-feed/medrxiv-15-deep-learning-reveals-prognostic-information-beyond-ajcc-stage-in-routine.md)
- [Single‑cell atlas of 189 colorectal tumors links tumor biology to worse outcomes in young patients](https://medichelpline.com/clinical-feed/stat-news-0-stat-new-atlas-of-colorectal-tumors-sheds-light-on-why-cancers-in-young-people.md)
- [Cellular Metabolism, Immunity, and Oncogenesis: Drug Discovery Opportunities](https://medichelpline.com/clinical-feed/frontiers-in-immunology-5-editorial-cellular-metabolism-the-immune-system-and-oncogenesis-opportunities.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.